La Jolla Pharmaceutical Company Files Marketing Authorization Application For European Regulatory Approval Of Riquent

... La Jolla PharmaceuticalCompany (Nasdaq: LJPC) today announced that its Marketing AuthorizationApplication (MAA) has been accepted for review by the European MedicinesAgency (EMEA) for potential approval to market Riquent(R) (abetimussodium), its drug candidate for lupus renal disease, in the European Union(EU). The MAA was filed with the EMEA on March 31, 2006. [click link for full article] ...